Lewisy antigen (blood group 8, BG8) is a useful marker in the histopathological differential diagnosis of flat urothelial lesions of the urinary bladder

Journal of Clinical Pathology

Volumn 64, Issue 8, 2011, Pages 672-676

  Gunia, Sven ^a   Kakies, Christoph ^b   May, Matthias ^c   Koch, Stefan ^a   Erbersdobler, Andreas ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

^c St Elisabeth Clinic Straubing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOMA; BLADDER MUCOSA; BLOOD GROUP A; BLOOD GROUP LEWIS SYSTEM; CARCINOMA IN SITU; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; UROTHELIUM;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA IN SITU; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LEWIS BLOOD-GROUP SYSTEM; MALE; MIDDLE AGED; OBSERVER VARIATION; PRECANCEROUS CONDITIONS; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 79960731108     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200065     Document Type: Article

References (26)

1. McKenney JK, Gomez J A, Desai S, et al. Morphologic expressions of urothelial carcinoma in situ. Am J Surg Pathol 2001;25:356-62.
2. Montifori R, Chen L, Lopez-Beltran A, et al. Inverted (endophytic) noninvasive lesions and neoplasms of the urothelium: the cinderella group has yet to be fully exploited. Eur Urol 2011;59:225-30.
3. McKenney JK, Desai S, Cohen C, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol 2001;25:1074-8. (Pubitemid 32685906)
4. Cheng L, Cheville JC, Neumann RM, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999;85:2469-74. (Pubitemid 29244858)
5. Wolf H, Melsen F, Pedersen SE, et al. Natural history of carcinoma in situ of the urinary bladder. Scand J Urol Nephrol Suppl 1994;157:147-51. (Pubitemid 24205663)
6. Roupret M, Zigeuner R, Palou J, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011;59:584-94.
7. Williamson SR, Montironi R, Lopez-Beltran A, et al. Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: the state of the art. Crit Rev Oncol Hematol 2010;76:112-26.
8. Yin M, Bastacky S, Parwani AV, et al. p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situ. Hum Pathol 2008;39:527-35.
9. Hodges KB, Lopez-Beltran A, Davidson DD, et al. Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum Pathol 2010;41:155-62.
10. Brandau S, Böhle A. Bladder cancer. I. Molecular and genetic basis of carcinogenesis. Eur Urol 2001;39:491-7. (Pubitemid 32678962)
11. Murali R, Delprado W. CD10 immunohistochemical staining in urothelial neoplasms. Am J Clin Pathol 2005;124:371-9. (Pubitemid 41232923)
12. Kajiwara H, Yasuda M, Kumaki N, et al. Expression of carbohydrate antigens (SSEA-1, sialyl-Lewis X, DU-PAN2 and CA19-9) and E-selectin in urothelial carcinoma of the renal pelvis, ureter, and urinary bladder. Tokai J Exp Clin Med 2005;30:177-82. (Pubitemid 41704060)
13. Lapham RL, Grignon D, Ro JY. Pathologic prognostic parameters in bladder urothelial biopsy, transurethral resection, and cystectomy specimens. Semin Diagn Pathol 1997;14:109-22. (Pubitemid 27233149)
14. Orntoft TF, Meldgaard P, Pedersen B, et al. The blood group ABO gene transcript is down-regulated in human bladder tumors and growth stimulated urothelial cell lines. Cancer Res 1996;56:1031-6. (Pubitemid 26065396)
15. Juhl BR. Blood group antigens in transitional cell tumours of the urinary bladder. An immunohistochemical study. Dan Med Bull 1994;41:1-11. (Pubitemid 2044234)
16. Eble J, Sauter G, Epstein JI, et al, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004:110-23.
17. Oxley JD, Cottrell AM, Adams S, et al. Ketamine cystitis as a mimic of carcinoma in situ. Histopathology 2009;55:705-8.
18. Morikawa T, Maeda D, Kume H, et al. Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology 2010;57:885-92.
19. Riera JR, Astengo-Osuna C, Longmate JA, et al. The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997;21:1409-19. (Pubitemid 27528251)
20. Ordóñez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44s immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598-606. (Pubitemid 30180755)
21. Politi E, Kandaraki C, Apostolopoulou C, et al. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005;32:151-5. (Pubitemid 40256264)
22. King JE, Thatcher N, Pickering CA, et al. Sensitivity and specifity of immunohistochemical markers used in the diagnosis of epitheloid mesothelioma: a detailed systematic analysis using published data. Histopathology 2006;48:223-32.
23. Yziji H, Battifora H, Barry TS, et al. Evaluation of 12 antibodies for distinguishing epitheloid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specifity. Mod Pathol 2006;19:514-23.
24. Blaszczyk-Thurin M, Ramachandran M, Westerink MA, et al. Molecular recognition of the Lewis Y antigen by monoclonal antibodies. Protein Eng 1996;5:447-59. (Pubitemid 26169558)
25. Moro-Rodriguez E, Alvarez-Fernández E. Losses of expression of the antigens A, Lea and Lex and over-expression of Ley in carcinomas and HG-SIL of the uterine cervix. Diagn Pathol 2008;11:38.
26. Weimann A, Rieger A, Zimmermann M, et al. Comparison of six immunohistochemical markers for the histologic diagnosis of neoplasia in Barrett's esophagus. Virchows Arch 2010;457:537-45.